Compare Charles River Laboratories Intl. Inc (CRL) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Petróleo Brasileiro SA — how do they compare? Charles River Laboratories Intl. Inc trades at $285.37 (market cap $13.46B), while Petróleo Brasileiro SA trades at $17.78 (market cap $112.19B). The key difference: Petróleo Brasileiro SA is far larger — about 8.3× Charles River Laboratories Intl. Inc's market cap, and Petróleo Brasileiro SA pays a 9.42% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | PBR | |
|---|---|---|
Market Cap | $13.46B | $112.19B |
Sector | Health | Technology |
52-Week High | $282.00 | $22.03 |
52-Week Low | $145.57 | $11.54 |
Enterprise Value | $16.30B | $172.61B |
Dividend Yield | — | 9.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
PBR trades at $17.91, down 2.29% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a low P/E of 4.53 and robust profitability with a 24.52% net income margin. Recent Q2 2026 earnings beat expectations, with net profit nearly doubling year-over-year, driven by record production and higher oil prices (Reuters, 2026-08-06).
The investment case is supported by attractive valuations and strong cash flows, but faces headwinds from technical selling pressure and regulatory uncertainty. Analyst consensus is bullish with 50% buy ratings, though near-term price action may remain volatile amid broader market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
